Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

ASH Announces Partnership with the University of North Carolina, a ClinGen Grantee, to Curate Genomic Data for Blood Disease Research

(ASH) Apr 5, 2018 - The American Society of Hematology (ASH) today announced a partnership with the University of North Carolina at Chapel Hill (UNC), a National Institutes of Health (NIH) Clinical Genome Resource (ClinGen) grantee, to develop a broad and accessible compendium of genomic data aimed at improving the diagnosis of some blood cancers and disorders.

read press release

Bayer to Showcase Data from Diverse Oncology Pipeline at AACR 2018

(Business Insider) Apr 5, 2018 - Bayer will present research from its growing oncology portfolio at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago.

read article

FDA Accepts New Drug Application for Duvelisib and Grants Priority Review

(Verastem) Apr 9, 2018 - Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) for its lead product candidate duvelisib.

read corporate press release

Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018

(Amgen) Apr 9, 2018 - Data spans Amgen's early pipeline, including the first presentation of data for its most advanced chimeric antigen receptor (CAR) T cell therapy programs, targeting DLL3 in small cell lung cancer and FLT3 in acute myeloid leukemia (AML). In addition, pre-clinical data for Amgen's DLL3 CAR T cell therapy and bispecific T cell engager (BiTE®) program will be featured in an oral presentation.

read corporate press release

Cancer Docs Say 'Superblood' May Work Against Deadly Malignancies

(NBCNews.com) Apr 2, 2018 - New therapy seen as possible treatment for pancreatic cancer and triple-negative breast cancer, among others.

read article

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukaemia

(AstraZeneca) Apr 3, 2018 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia (HCL) who have received at least two prior lines of therapy.

read corporate press release

FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

(Amgen) Mar 29, 2018 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

read corporate press release

Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)

(Yahoo! Finance) Apr 3, 2018 - Prexigebersen plus LDAC was well-tolerated and showed early anti-leukemic activity in nearly 50% of evaluable AML patients treated to date; planned protocol amendments may provide for potential approvals in the U.S. and Europe of two prexigerbesen combination treatments.

read article

Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?

(Regulatory Focus) Apr 2, 2018 - Last week, the US Food and Drug Administration (FDA) expanded the approval of Amgen’s Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD).

read article

Payments To Doctors Linked To Prescription Practices For Two Cancer Types

(UNC Lineberger CCC) Apr 9, 2018 - Physicians who received payment from pharmaceutical companies for meals, talks and travel were more likely to prescribe those companies’ drugs for two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led study has found.

read article

Cancer Drug Choices Tied To Drugmaker Payouts To Doctors

(Reuters Health) Apr 9, 2018 - Some oncologists may be more likely to prescribe certain cancer medicines when they receive payments from the companies that make these drugs, a U.S. study suggests.

read article

Three Solutions to Maximize the Clinical Benefit and Affordability of Targeted Cancer Drugs

(Penn LDI) Apr 18, 2018 - Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer. One of the biggest drivers of this growth is targeted cancer drugs.

read article

Discovery Adds To Evidence That Some Children Are Predisposed To Develop Leukemia

(St. Jude Children's) Apr 19, 2018 - St. Jude Children's Research Hospital scientists have discovered a fourth gene that can predispose carriers to the most common childhood cancer, expanding the list of genes to include in cancer screening.

read press release

Chip-Based Blood Test For Multiple Myeloma Could Make Bone Biopsies A Relic Of The Past

(University of Kansas) Apr 19, 2018 - The days of using bone biopsies to guide treatment for multiple myeloma and other cancers, such as many types of leukemia, may be numbered.

read press release

For Young Adults with Blood Cancer, Pediatric Centers May Improve Survival

(ASH) Apr 17, 2018 - Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study.

read press release

Science Hinted That Cancer Patients Could Take Less Of A $148,000-a-year Drug. Its Maker Tripled The Price Of A Pill.

(Washington Post/Wonkblog) Apr 18, 2018 - A group of cancer doctors focused on bringing down the cost of treatments by testing whether lower — and cheaper — doses are effective thought they had found a prime candidate in a blood cancer drug called Imbruvica that typically costs $148,000 a year.

read article (free registration required)

Gene Therapy in Community Practices—Administering CAR-T Therapies

(AJMC.com Managed Markets Network) Apr 15, 2018 - While immune-based treatments have gained significant strides in cancer care, chimeric antigen receptor (CAR)-T cells have also started to make their mark. With 2 treatments approved so far for liquid cancers, the extent of remission has surprised the field.

read article

An Off-the-Shelf, Dual-Targeted CAR T-Cell Product Showed Promising Results in Preclinical Studies

(AACR 2018) Apr 16, 2018 - FT819, an off-the-shelf, T-cell receptor (TCR)-less CD19 CAR T-cell product that could potentially be made more accessible to cancer patients than conventional CAR T-cell therapies showed positive results in preclinical specificity, functionality, and efficacy studies, according to data presented at the AACR Annual Meeting 2018, April 14-18.

read press release

How Does Leukemia Escape From Immunotherapy?

(Fred Hutch News Service) Apr 16, 2018 - A new study highlights one way that an aggressive leukemia can wriggle its way free of targeted attack by a high-tech strategy for immune-based therapy.

read article

Pfizer: EU Approves Mylotarg In Combination With Chemotherapy To Treat AML

(RTTNews.com) Apr 23, 2018 - Pfizer Inc. said that the European Commission has approved Mytolarg, or gemtuzumab ozogamicin, in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia or AML, except acute promyelocytic leukemia or APL.

read article
Next Page